Literature DB >> 2536599

Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men.

L F Roy1, R I Ogilvie, P Larochelle, P Hamet, F H Leenen.   

Abstract

To assess the contribution of venous effects to the hemodynamic changes caused by atrial natriuretic factor (ANF), the cardiac and peripheral effects of ANF were compared with those induced by the venoarterial vasodilator sodium nitroprusside. On 3 different days, eight healthy subjects received 2-hour infusions of either ANF, sodium nitroprusside, or placebo, by a single-blind crossover design. ANF was administered at a rate of 15 ng/kg/min for hour 1 and 50 ng/kg/min for hour 2; each infusion rate was preceded by a 50-micrograms bolus. The lower ANF infusion rate increased plasma cGMP fourfold, but only modest cardiovascular effects (small decreases in left ventricular end-diastolic and end-systolic volumes) were noted. At the higher ANF infusion rate, left ventricular volumes and intravascular volume, as indirectly assessed by changes in hematocrit levels, decreased further, which resulted in decreases in stroke volume, cardiac index, and systolic blood pressure. No evidence for arterial vasodilation (no decrease in diastolic blood pressure, total peripheral resistance, or forearm resistance) was obtained, and no increase in sympathetic activity was noted. In contrast, sodium nitroprusside caused arterial vasodilation, an increase in cardiac index, and significant increases in sympathetic activity. We conclude that short-term increases in plasma ANF within the physiologic range primarily affect the venous vascular bed (by decreasing intravascular volume or by venodilation) without increasing sympathetic activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536599     DOI: 10.1161/01.cir.79.2.383

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Abnormalities in arterial-ventricular coupling in older healthy persons are attenuated by sodium nitroprusside.

Authors:  Paul D Chantler; Amit Nussbacher; Gary Gerstenblith; Steven P Schulman; Lewis C Becker; Luigi Ferrucci; Jerome L Fleg; Edward G Lakatta; Samer S Najjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-04       Impact factor: 4.733

2.  Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure.

Authors:  J M Costello; C L Backer; P A Checchia; C Mavroudis; R G Seipelt; D M Goodman
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

3.  Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase.

Authors:  J F Arnal; L Warin; J B Michel
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Atrial natriuretic peptide decreases hepatic and cardiac blood content, but increases intestinal blood content in supine humans.

Authors:  J Peters; D Neuser; W Schaden; J O Arndt
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

5.  Plasma cyclic guanosine 3'-5' monophosphate concentrations and low vascular resistance in human septic shock.

Authors:  F Schneider; P Lutun; A Couchot; P Bilbault; J D Tempé
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

6.  Atrial natriuretic peptide alters neither capillary filtration nor vascular compliance of both skin and skeletal muscle of humans.

Authors:  T Rölleke; B Berke; J O Arndt
Journal:  Basic Res Cardiol       Date:  1994 Mar-Apr       Impact factor: 17.165

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.